SCHEDULE 13G: Ikarian Capital and Neil Shahrestani Disclose 9.99% Stake in Traws Pharma, Inc.
Beneficial Ownership Report
Investment firm Ikarian Capital, LLC and its sole manager Neil Shahrestani have disclosed a 9.99% beneficial ownership stake in Traws Pharma, Inc., including shares acquirable through warrants.
Summary
- Ikarian Capital, LLC and Neil Shahrestani jointly reported beneficial ownership of 394,255 shares of Traws Pharma, Inc. common stock.
- This represents 9.99% of the company's outstanding common stock.
- The reported ownership includes 295,762 shares that can be acquired within 60 days through warrants.
- The exercise of these warrants is subject to a restriction preventing the Reporting Persons' beneficial ownership from exceeding 9.99% of the outstanding shares.
- The 9.99% ownership calculation is based on a total of 3,946,493 shares of common stock outstanding, which includes the 295,762 warrant shares and 3,650,731 shares outstanding as of January 31, 2025.
- The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts advised by Ikarian Capital.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, containing no subjective language or performance data to indicate positive or negative sentiment.
Risks
- The Reporting Persons' ability to convert warrants is restricted to prevent their beneficial ownership from exceeding 9.99% of Traws Pharma, Inc.'s outstanding common stock.
Future Outlook
NA
Industry Context
NA
Related Party Transactions
- Ikarian Capital, LLC serves as an investment manager to Ikarian Healthcare Master Fund, L.P. and as sub-adviser to certain separately managed accounts, which are the record owners of the securities.
- Neil Shahrestani indirectly controls Ikarian Capital, LLC and is therefore deemed to indirectly beneficially own the securities held by Ikarian Capital.
Stakeholder Impact
- Shareholders: The disclosure of a significant 9.99% stake by an investment firm and its principal could signal investor confidence or potential future engagement, which may influence other investors' perceptions.
Key Dates
| Date | Description |
|---|---|
| 2024-12-31 | Date of event which requires filing of this statement. |
| 2025-01-31 | Date as of which 3,650,731 shares of Common Stock were outstanding, as disclosed in the Issuer's Definitive Proxy Statement. |
| 2025-02-06 | Date the Issuer's Definitive Proxy Statement was filed with the U.S. Securities and Exchange Commission. |
| 2025-02-14 | Date of signature for the Schedule 13G filing. |
Keywords
Traws Pharma Inc., Ikarian Capital LLC, Neil Shahrestani, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Adviser, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.